Use of CRF antagonists and related compositions
AssigneePfizer Inc.
InventorYuhpyng L. Chen
Life of this patent
Estimating the term…
Abstract
A corticotropin releasing factor (CRF) antagonist is administered to treat a condition selected from the group consisting of: c) disorders that can be treated by altering circadian rhythm; and d) depression, further wherein a second compound for treating depression is administered, the second compound for treating depression having an onset of action that is delayed with respect to that of the CRF antagonist.
Claims10
A method of treating a condition comprising administering a corticotropin releasing factor (CRF) antagonist in an amount effective to treat said condition, wherein said condition is selected from the group consisting of:
- a) disorders that can be treated by altering circadian rhythm;
- and
- b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist.
A pharmaceutical composition for the treatment of a condition selected from the group consisting of:
- a) abnormal circadian rhythm;
- and
- b) depression;
- comprising an amount of a CRF antagonist effective to treat said condition in combination with a pharmaceutically acceptable carrier,
- wherein where said condition is depression, said depression is treated with a second compound for treating depression, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist.
The pharmaceutical composition of claim 0 for treatment of depression comprising an amount of a CRF antagonist effective to treat said depression, and said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist.
A method for treating or preventing a cardiovascular disease comprising administering a CRF antagonist, or a pharmaceutically acceptable salt, isomer, or prodrug thereof, in combination with a non-CRF antagonist compound for treating said disease.
A method for treating migraine or non-migraine headache comprising administration of a CRF antagonist in combination with a non-CRF antagonist compound that treats said headache.
The method of claim 0 wherein said non-CRF antagonist compound is selected from the group consisting of non-steroidal anti-inflammatory drugs, anti-emetics, ergotamine, and agents that modulate serotonin receptors or mimic the effects of serotonin.
A method for treating emesis comprising administration of a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis.
Dependencies are inferred from the claim text.